NAD+ vs niacin comes down to a simple difference: niacin is vitamin B3, which the body uses to make NAD+. NAD+ is the helper molecule cells build from those ingredients. They aren't the same substance, and neither is an automatic substitute for the other.

The reason for considering one matters. Meeting a vitamin need, treating cholesterol and requesting prescribed NAD+ are three different medical questions.

NAD+ vs niacin: what the names mean

Niacin names a vitamin family. On a supplement label, it most often means nicotinic acid or nicotinamide, also called niacinamide. Both supply material for NAD+, but their effects can differ.

NAD+ stands for nicotinamide adenine dinucleotide. It's a coenzyme, a small molecule that helps enzymes work. Enzymes are proteins that carry out chemical reactions. NIH's niacin fact sheet explains this vitamin-to-coenzyme connection.

Name What it is Why the distinction matters
Niacin The vitamin B3 family A nutrition label may use this broad name
Nicotinic acid One form of B3 The form used in major cholesterol trials
Nicotinamide, or niacinamide Another form of B3 Supplies NAD building blocks without the same cholesterol effects
NAD+ The coenzyme cells assemble Giving the coenzyme asks a separate treatment question

A precursor simply means an ingredient the body can turn into another molecule. The history of NAD follows how researchers discovered that vitamin connection.

The plus sign identifies a chemical form, rather than a vitamin grade. The NAD+ and NADH comparison explains those related forms.

Getting enough B3 is a nutrition question

NIH's nutrition guidance lists adult daily recommended amounts of 14 mg niacin equivalents for women and 16 mg for men. Pregnancy and breastfeeding have higher recommendations. Niacin equivalents count both dietary niacin and the contribution from tryptophan, a protein building block the body can convert.

Those numbers describe ordinary nutrition. They aren't NAD+ prescription amounts and don't provide a conversion between a vitamin and a medication.

Most people in the United States get enough niacin from food. Poultry, fish, nuts, beans and enriched grains are common sources. Severe deficiency can cause pellagra, a disease affecting the skin, digestion and nervous system.

A clinician assessing possible deficiency considers diet and conditions that limit nutrition. Tiredness alone doesn't identify a missing vitamin. Treating a confirmed shortage and considering extra NAD+ require separate assessments.

What did the high-dose niacin heart trials test?

The AIM-HIGH trial in the New England Journal of Medicine, 2011, enrolled 3,414 people with established heart or blood-vessel disease and low HDL cholesterol. HDL is the type often called “good” cholesterol.

Everyone received simvastatin, a cholesterol-lowering medicine; some also needed ezetimibe, another cholesterol medicine. Participants received extended-release niacin, a formulation that releases gradually, at 1,500–2,000 mg daily, or placebo, the study's comparison treatment.

Over about three years, the combined outcome of major heart and blood-vessel events affected roughly 16 in every 100 people in both groups. The figures were 16.4% with niacin and 16.2% with placebo. Blood fats improved, but adding niacin didn't reduce those events.

HPS2-THRIVE in the same journal, 2014, a later trial, also added extended-release nicotinic acid to statin treatment. Statins are cholesterol-lowering medicines such as simvastatin. The study paired niacin with laropiprant, a medicine intended to reduce skin warmth and redness called flushing. It found no significant reduction in major heart or blood-vessel events and more serious unwanted effects.

These results concern specific drug treatments in people with disease. Neither trial tested ordinary B3 nutrition. Neither tested nicotinamide or NAD+ injections.

New data: niacin can raise a blood NAD+ measurement

As of November 12, 2026, the day this article was written, a study published August 17, 2026 adds a direct niacin finding. Euro and colleagues in Redox Biology analyzed stored samples collected from eight healthy adults over 16 weeks of nicotinic acid use.

Blood NAD+ rose four- to sixfold, with different responses between people. Some also showed higher blood sugar and signs of reduced response to insulin, the hormone that controls blood sugar.

This small analysis didn't compare niacin with NAD+ injections or establish better energy or slower aging. A higher blood number isn't automatically a better health outcome.

Does niacin have the same side effects as NAD+?

The risks differ by molecule, amount and delivery method. Nicotinic acid can cause flushing, often with itching or tingling. Nicotinamide doesn't cause that familiar flush, but high doses can still harm the liver. High-dose nicotinic acid can also raise blood sugar and lower blood pressure, and long-term use, especially of extended-release forms, can cause liver problems including hepatitis and liver failure, as NIH's fact sheets explain.

Flushing isn't proof that NAD+ is rising or that treatment is helping. Its absence doesn't establish safety, either.

Injectable preparations add different concerns. FDA's October 30, 2024 ingredient-quality notice describes severe chills, shaking, vomiting and fatigue after NAD+ injectable drugs, with some people requiring medical treatment. FDA called these reactions consistent with excessive endotoxins, bacterial residue that can cause illness.

Those reports concern injectable drugs, rather than B3 in food. The NAD+ side-effects guide examines that separate evidence.

What changes with prescribed NAD+?

An NAD+ prescription concerns the coenzyme itself. Neither the heart trials nor the newer blood study provides a niacin-to-NAD+ injection dose conversion. The NAD+ decision guide covers the broader treatment discussion.

NAD+ prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

In its September 16, 2025 compounding Q&A, FDA explains that it doesn't verify compounded drugs' safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

What makes the comparison useful at a visit?

The discussion starts with the problem someone wants to address. A possible nutrient shortage calls for a nutrition assessment. A cholesterol question calls for review of the person's heart history and existing treatment. Interest in prescribed NAD+ calls for evidence about that preparation and the intended outcome.

Current medicines and supplements, previous reactions, and liver or blood-sugar problems help the clinician weigh those questions. Any prescribed amount and follow-up plan come from the prescriber. Study amounts don't choose a personal regimen.

The clinician can explain what would count as a useful change and when it would be reviewed. A blood result alone doesn't settle whether someone's daily life improved. The decision may involve investigating another cause of tiredness, reviewing existing care or considering treatment with a clear follow-up plan.

At Promise, a licensed provider reviews every request, and not everyone qualifies.